Bioxytran Inc (BIXT)
OTHER OTC:BIXT
US Market
Holding BIXT?
Track your performance easily

Bioxytran (BIXT) Income Statement

15 Followers

Bioxytran Income Statement

Last quarter (Q ), Bioxytran's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Bioxytran's net income was $-392.37K. See Bioxytran’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 1.24M$ 3.83M$ 2.14M$ 4.21M$ 1.27M$ -1.63M
Operating Income
$ -2.80M$ -3.82M$ -2.13M$ -4.21M$ -1.27M$ -1.82M
Net Non Operating Interest Income Expense
$ 543.55K$ 541.83K$ 519.55K$ -2.02M$ -1.01M$ -41.84K
Other Income Expense
------
Pretax Income
$ -2.97M$ -4.37M$ -2.66M$ -4.53M$ -2.54M$ -1.86M
Tax Provision
-----$ -794.25K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -2.94M$ -4.28M$ -2.46M$ -4.03M$ -2.48M$ -1.86M
Basic EPS
-$ -0.03$ -0.02$ -0.04$ -0.03-
Diluted EPS
-$ -0.03$ -0.02$ -0.04$ -0.03$ -0.02
Basic Average Shares
$ 613.96M$ 134.22M$ 115.14M$ 106.25M$ 93.97M$ 85.60M
Diluted Average Shares
$ 613.96M$ 134.22M$ 115.14M$ 106.25M$ 93.97M$ 92.92M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 1.23M$ 3.83M$ 2.14M$ 4.21M$ 1.27M$ -1.63M
Net Income From Continuing And Discontinued Operation
$ -2.94M$ -4.28M$ -2.46M$ -4.03M$ -2.48M$ -1.86M
Normalized Income
$ -2.83M$ -3.40M----
Interest Expense
------
EBIT
$ -1.09M$ -3.83M$ -2.14M$ -4.21M$ -1.27M$ -1.82M
EBITDA
$ -1.02M$ -3.82M$ -2.13M$ -2.19M$ -1.27M$ -1.63M
Currency in USD

Bioxytran Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis